PrEP Apretude LA denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for prep apretude la are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Step Therapy Before Apretude (Cabotegravir LA) — and How to Appeal

Aetna's step-therapy (also called "fail-first") protocols typically require that a member try one or more preferred, lower-cost drugs before a non-preferred agent is approved. For Apretude — the first long-acting injectable PrEP option — Aetna's protocol commonly requires a trial of a daily oral PrEP medication first. The appeal argument is that the injectable route is not therapeutically equivalent to daily oral PrEP for every patient: adherence barriers, clinical circumstances, and patient-specific factors can make the oral step clinically inappropriate.

### Why This Is Appealable

Step-therapy overrides are available under federal and most state laws when the required "step" drug is contraindicated, has been tried and failed, or is otherwise clinically inappropriate for the individual patient. Adherence to daily oral medication is a documented clinical challenge in PrEP; an injectable that removes the daily adherence requirement can represent a medically necessary — not merely preferred — alternative for a specific patient. Many states also have step-therapy reform laws that set a maximum step duration and mandate an exception process.

### Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 or ACA §2719, you have the right to a full-and-fair internal review. File within the deadline stated on your denial notice.
• External review: After a final internal denial, request IRO review within the four-month window under ACA §2719. The IRO applies clinical standards, not just plan policy.
• Expedited review: Available when delay would seriously jeopardize health — decision typically required within 72 hours.

### Documentation to Gather

1. Prescriber letter — must explain why daily oral PrEP is clinically inappropriate or insufficient for this specific patient (e.g., documented or anticipated adherence barriers, comorbidities, patient history), and why the injectable formulation is medically necessary rather than merely preferred. 2. History of any prior oral PrEP trial — dates started and stopped, documented reasons for discontinuation or inadequate adherence, labs or refill records. 3. Aetna's step-therapy exception criteria — obtain the Clinical Policy Bulletin and list every exception pathway. Address each one explicitly in the appeal. 4. FDA prescribing label for Apretude — shows that the injectable schedule is a distinct clinical approach, not a dose adjustment of an oral product. 5. Applicable guideline reference — cite the relevant guideline organization (e.g., CDC, USPSTF) generically to support the clinical rationale without quoting specific numeric thresholds.

### Criteria-Mapping Structure

Create a two-column table. Left column: each step-therapy exception criterion from Aetna's policy. Right column: the specific chart fact, date, or prescriber statement that satisfies it. Attach this table to your appeal letter. A structured response forces item-by-item review rather than a blanket re-denial.

### State Law Considerations

If you are in a state with a step-therapy override law, cite that statute in your appeal. These laws typically require the insurer to grant an exception within a defined number of days and set limits on how many steps can be required. Your state insurance commissioner's office can confirm whether your plan is subject to state step-therapy protections.

### Next Step

If Aetna denies the internal appeal, escalate to external review immediately. An IRO will evaluate whether the step-therapy protocol, as applied to your specific clinical situation, is consistent with generally accepted medical practice — and injectable PrEP has strong clinical guideline support for appropriate candidates.